Sagent Pharmaceuticals, Inc. (SGNT) Posts Q3 Loss of $0.17, Sales Top Expectations
Tweet
Share
E-mailGet Alerts SGNT Hot Sheet
Join SI Premium – FREE
Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q3 EPS of ($0.17), $0.05 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $41.3 million versus the consensus estimate of $40.97 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
- Scholastic Corp (SCHL) Misses Q1 EPS by 23c
- NeoVolta Inc. (NEOV) Misses Q3 EPS by 17c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
